1820 related articles for article (PubMed ID: 17030655)
1. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
[TBL] [Abstract][Full Text] [Related]
3. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
5. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients.
Geleijnse JM; Giltay EJ; Kromhout D
Alzheimers Dement; 2012 Jul; 8(4):278-87. PubMed ID: 21967845
[TBL] [Abstract][Full Text] [Related]
6. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
8. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
9. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study.
Irving GF; Freund-Levi Y; Eriksdotter-Jönhagen M; Basun H; Brismar K; Hjorth E; Palmblad J; Vessby B; Vedin I; Wahlund LO; Cederholm T
J Am Geriatr Soc; 2009 Jan; 57(1):11-7. PubMed ID: 19054188
[TBL] [Abstract][Full Text] [Related]
11. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
da Silva TM; Munhoz RP; Alvarez C; Naliwaiko K; Kiss A; Andreatini R; Ferraz AC
J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
[TBL] [Abstract][Full Text] [Related]
13. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
Zhang Z; Wang X; Chen Q; Shu L; Wang J; Shan G
Zhonghua Yi Xue Za Zhi; 2002 Jul; 82(14):941-4. PubMed ID: 12181083
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
[TBL] [Abstract][Full Text] [Related]
16. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.
Lu PH; Masterman DA; Mulnard R; Cotman C; Miller B; Yaffe K; Reback E; Porter V; Swerdloff R; Cummings JL
Arch Neurol; 2006 Feb; 63(2):177-85. PubMed ID: 16344336
[TBL] [Abstract][Full Text] [Related]
17. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
18. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
19. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.
Caballero J; Hitchcock M; Scharre D; Beversdorf D; Nahata MC
Clin Ther; 2006 Oct; 28(10):1695-700. PubMed ID: 17157125
[TBL] [Abstract][Full Text] [Related]
20. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
Frölich L; Ashwood T; Nilsson J; Eckerwall G;
J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]